iAnthus Capital Holdings, Inc.

iAnthus Capital Holdings, Inc. owns and operates licensed cannabis cultivation, processing, and dispensary facilities in the United States. It offers biomass products, such as pre-rolls; cannabis infused products, including topical creams and edibles; vape cartridges, concentrates, live resins, wax products, oils, and tinctures; cannabidiol products, such as topical creams, tinctures, and sprays, as well as products for beauty and skincare that include lotions, creams, haircare products, lip balms, and bath bombs. The company engages in the wholesale-distribution and retail of CBD products. It owns and/or operates 32 dispensaries and 10 cultivation and/or processing facilities in 8 states. The company was founded in 2014 and is headquartered in New York, New York.

iAnthus Capital Holdings, Inc. trades as ITHUF on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $143.99M of revenue and -$40.91M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

iAnthus Capital Holdings, Inc. can be compared against peers such as Atlas Energy Corp., The Cannabist Company Holdings Inc., Fluent Corp., Global Cord Blood Corporation, Elixxer Ltd., Ecofibre Limited.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $34.86M, beta of -0.70, and return on equity of +39.7%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

ITHUF currently shows total debt of $227.54M and beta of -0.70. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: DEFA14A (2026-05-26 00:00:00), DEF 14A (2026-05-19 00:00:00), 4 (2026-05-15 00:00:00), 8-K (2026-05-12 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.ianthus.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.